Chimera Research Group

previous arrow
next arrow

February 27th Biotech Update

It was a good start to the week albeit on limited news.  I actually find it encouraging to see what looks like a breakout on no major news as it speaks to an underlying bid in the sector.  Obviously major news can always change the tone of the market but it is certainly a good […]

February 23rd Biotech Update

We are very close to breaking out.  I think it would be a nice way to end the week to get that initial breakout and run higher but there is actually not a lot of news that could drive it.  Rates expectations are a little less dovish with most now not expecting the first rate […]

February 22nd Biotech Update

Are we at the pullbacks that refresh stage?  The past couple of days have not been great but we are still hanging out at the top end of the range.  This bouncing around at these levels is resetting any overbought conditions and makes a breakout more likely to cause a run as opposed to being […]

February 20th Biotech Update

We are very close to breaking out on the XBI.  One more very strong day or a couple days of strength would be enough.  I think the charts are not that overbought and so we have a decent chance to sustain the breakout but one could also look at the chart and see a clear […]

Mailing List



Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.

The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.

Subscribe to Chimera Research Group and proceed with confidence.

Get Started

Recent Press


Log In

JoinLost Password?